Ziltivekimab. CagriSema. Monlunabant. BVCT Shared those NO-GOs with Novo Leadership Before the Readouts.
BVCT sealed NO-GO calls on ziltivekimab (ZEUS) and CagriSema (REIMAGINE 4) on , and on monlunabant on ; all three were sent to Novo Nordisk R&D on . The readouts followed on , and ; classified True Negative (TN), True Negative (TN) and True Negative (TN).
In our view, Novo Nordisk could have maintained its leading position with BVCT.
The gap to Eli Lilly now exceeds USD 800 billion.
On , Novo Nordisk announced that ZEUS — a 6,385-patient cardiovascular outcomes trial of ziltivekimab in ASCVD, CKD and inflammation — missed its primary endpoint. Three-point MACE came in at a hazard ratio of 0.99 vs. placebo (95% CI 0.88–1.11). Ziltivekimab engaged its target precisely as designed: free IL-6 fell, hsCRP fell, yet none of it converted into cardiovascular benefit. Novo Nordisk said it will book a non-cash impairment charge in Q3 2026.
Eighteen days earlier, Guggenheim Securities told investors that success was highly likely (Fierce Biotech) and a clinically significant benefit probable (Fierce Biotech), defining that as HR 0.85. 45 days earlier, Morgan Stanley projected a greater than 15% reduction in cardiovascular risk and USD 3 billion in peak sales, rising to USD 5 billion across indications (MedWatch). BMO put the odds of a ≥15% benefit at 55%. Consensus peak sales sat at roughly USD 3 billion (Investing.com via Yahoo Finance).
BVCT sealed the opposite call on — 859 days before the readout — and sent it to Novo Nordisk twice: shared with Novo R&D on with its timestamped record, and re-sent on , sixteen weeks before ZEUS reported.
ZEUS is not the only one. BVCT sealed NO-GO calls on CagriSema and monlunabant on the same basis, and sent both to Novo Nordisk ahead of their readouts. The CagriSema calls were shared with Novo Nordisk on — 389 days before the first CagriSema-versus-tirzepatide readout existed (Reuters).
In our view, just as with Sanofi, Novo Nordisk could have used BVCTs and made correct NO-GO decisions before initiation — saving multi-billion-dollar R&D cost, and sparing tens of thousands of patients from trials that were never going to help them — with no patient data, from the mechanism alone.
In our view, the opportunity cost of not adopting BVCT is not only the impairment charge. It is the USD 800 billion-plus market-capitalisation gap that has opened between Novo Nordisk and Eli Lilly while these programmes ran.
Three Sealed NO-GOs.
Ziltivekimab, CagriSema and monlunabant. Three assets, three sealed NO-GO calls, each timestamped and each sent to Novo Nordisk R&D before its trial readout was announced.
partial SUCCESS (statistically maybe significant yet weak additive clinical benefit to SoC in MACE reduction)
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit to SoC with inferior-to-semaglutide efficacy in MACE)
Novo Nordisk A/S · Ziltivekimab (anti-IL-6 ligand mAb) · ZEUS · NCT05021835 · Phase 3 · 6,385 patients · ASCVD + Chronic Kidney Disease + Inflammation (hsCRP ≥ 2 mg/L). Quantified to Novo Nordisk R&D by email on : the effect size of ziltivekimab as an add-on [therapy] in MACE would have an HR > 1.1 compared with semaglutide as an add-on [therapy]. Outcome: Primary endpoint missed. Three-point MACE HR 0.99 compared with placebo (95% CI 0.88–1.11). Target engagement confirmed — free IL-6 and hsCRP both reduced — with no translation into MACE benefit. Higher rate of serious infections versus placebo. No difference in all-cause mortality. Novo Nordisk said it will book a non-cash impairment charge in Q3 2026. CORRECT NO-GO — called 859 days in advance and sent to Novo Nordisk 547 days before readout. The dashboard classifies the readout as True Negative (TN). Source: Novo Nordisk announcement, . BVCT PandaDoc Ref: HZADT-7RSIQ-FTU6M-CSDOS
partial SUCCESS (statistically significant yet moderate clinical benefit in HbA1c and weight reduction)
Commercial Prediction
FAILURE (commercially insufficient clinical benefit inferior to tirzepatide in both HbA1c and weight reduction)
Novo Nordisk A/S · CagriSema (cagrilintide + semaglutide) · NCT06221969 · Phase 3 · Type 2 Diabetes · 1,024 patients · head-to-head versus tirzepatide. Sent to Novo Nordisk R&D on , stating in terms: We’ve predicted the inferiority of CagriSema to Tirzepatide for both HbA1c and weight reduction endpoints for T2DM patients in the ongoing clinical trial NCT06221969. Outcome: CagriSema 15.2% weight loss against tirzepatide 15.8%. CagriSema HbA1c reduction 1.9 percentage points against tirzepatide 2.2 percentage points. Novo Nordisk reported non-inferiority on weight but not on HbA1c. CORRECT NO-GO — called 863 days in advance and sent to Novo Nordisk 551 days before readout. The dashboard classifies the readout as True Negative (TN). Source: Novo Nordisk financial report, . BVCT PandaDoc Ref: XLYLU-BJH5D-TU3AM-JVXCY
partial FAILURE (statistically insignificant additive clinical benefit in UACR) partial SUCCESS (statistically significant yet moderate additive clinical benefit in UPCR)
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in eGFR)
Novo Nordisk A/S · Monlunabant (INV-202, oral CB1 inverse agonist) · NCT05514548 · Phase 2 · 265 patients (enrolled, per the registry) · Diabetic Kidney Disease. Outcome: Reported in Novo Nordisk’s FY2024 financial report on : the trial missed its primary endpoint on uACR at 16 weeks across 10 mg and 25 mg doses. Neuropsychiatric adverse events were more frequent than placebo. CORRECT NO-GO — called 203 days in advance and sent to Novo Nordisk 6 days before readout. The dashboard classifies the readout as True Negative (TN). Source: Novo Nordisk FY2024 financial report, . BVCT PandaDoc Ref: 6OFXK-QKFHW-DGCDN-ULVDV
On , with ZEUS, BVCT also sealed separate ziltivekimab calls on two heart-failure trials, HERMES (No. 1526) and ATHENA (No. 1525). Their readouts came after : further development of both was discontinued on after a data monitoring committee futility finding; the dashboard classifies the HERMES readout as True Negative (TN) and the ATHENA readout as True Negative (TN). The three ziltivekimab trials are set out in the ziltivekimab case study; ATHENA, called before its first patient was enrolled, has its own page.
Ziltivekimab, sealed the same day: two more trials
partial SUCCESS (statistically maybe significant yet weak additive clinical benefit to SoC in KCCQ-CSS and 6MWD)
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit to SoC with inferior-to-semaglutide efficacy in KCCQ-CSS and 6MWD)
BVCT Identified the Biological Root Causes.
BVCT’s identified mechanistic root cause, sent to Novo Nordisk R&D on , was this: ziltivekimab’s weak efficacy follows from the mixed clinical impact of the IL-6 inhibition mechanism itself, which carries both pro-MACE and anti-MACE clinical impacts that are highly sensitive to the precise clinical setting of ASCVD + CKD + inflammation patients.
Novo Nordisk’s announcement describes precisely that dissociation. Ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive protein (Novo Nordisk) — and this did not translate into MACE risk reduction. The ziltivekimab case study sets out the rest of Novo Nordisk’s announcement.
The mechanistic rationale behind both the CagriSema and the ziltivekimab NO-GO was sent to Novo Nordisk by email, before either readout — the CagriSema inferiority thesis on , the IL-6 root cause on . Both were generated prior-data-independently: no Novo Nordisk data, no patient-level data from any trial, and no NDA. Nothing in these calls depended on privileged access — only on simulating the mechanism based on public information.
The molecule did what it was designed to do by hitting the target and improving the biomarker. The patient did not benefit. In our view, that biomarker-efficacy discordance is only visible with BVCT’s reliable causal simulations of the underlying mechanisms in proprietary virtual patients, without requiring real patients.
The Opportunity Cost.
The INTELLIGENCE, and the Value That Followed It
BVCT seals No. 1524 — NO-GO on ziltivekimab for ZEUS trial, commercially insufficient versus standard of care.
BVCT seals No. 1516 — NO-GO on CagriSema for REIMAGINE-4 trial, inferior to tirzepatide in both HbA1c and weight reduction.
Jun 2024Novo Nordisk reaches its all-time high market capitalisation. USD 636bn.
Prediction shared with Novo Nordisk R&D — eighteen months before the readout.
Prediction re-sent to Novo Nordisk R&D with its timestamped record (see No. 1524 on the dashboard; PandaDoc Ref in the record note).
ZEUS misses its primary endpoint. HR 0.99 (0.88–1.11) vs. placebo. −USD 30bn in a single day, Forbes reported.
REIMAGINE-4 shows CagriSema is not superior to tirzepatide. Novo Nordisk’s US-listed shares fell about 6% that day after guidance that, CNBC reported, appeared to disappoint investors; the same Q2 results included the REIMAGINE 4 HbA1c miss.
Aug 2026Novo Nordisk then — against Eli Lilly at roughly USD 1.1 trillion. USD 201bn, −68% from peak.
In our view, Novo Nordisk has repeated three times the same failure mode BVCT exists to interrupt: GO decisions were not clinically derisked before committing capital and manpower. Ziltivekimab, CagriSema and monlunabant were each called NO-GO before their trial readouts were announced.
Why This Matters to Your Board.
ZEUS is the cleanest demonstration available of the failure mode that escapes the best practice of conventional decision-making in big pharma companies. There was no execution error, no enrolment problem, no dosing miss. The drug hit its target with textbook precision yet generated no clinical benefit. Target engagement is not clinical benefit, and no amount of phase 2 biomarker data will tell you which is which.
BVCT resolves that question by simulating the causal mechanism inside virtual patients defined by the actual trial stratum — no patient-level data from the trial being predicted, and none from any prior trial. That is why the call could be made on regardless of the actual patient enrollment status.
This timestamped prediction was sent to Novo Nordisk on — eighteen months before ZEUS reported.
BVCT’s prospective record now stands at 674 of 705 scored ex-ante clinical predictions correct — 95.6% accuracy, 89.7% PPV (GO calls), 99.1% NPV (NO-GO calls), F1 of 93.8% — in the cohort frozen on 24 Sep 2026, against a 28.9% industry baseline (BIO / QLS / Informa 2011–2020, Phase II transition success rate). No. 1524 is one sealed record within it.
Compelling evidence shows that BVCT is a mature causal-biological, prior-data-independent, before-decision clinical derisking capability for pharma decision-makers. It’s a strategic imperative for pharma leadership to adopt BVCT in the best interest of patients.
Derisk your next GO decision in 7 days.
Name any asset in your portfolio, the indication, the patient stratum, and the comparator standard of care. Receive a simulated Phase-III effect size, a GO / NO-GO call against your own threshold, and the mechanistic root cause behind it — within one week. No patient data required. No model training. Sealed and timestamped, so the call can be verified against the readout, exactly as No. 1524 ZEUS was.